PMR

The S&P 500 and the Nasdaq chain losses following the rise in unemployment insurance claims

The S&P 500 and the Nasdaq chain losses following the rise in unemployment insurance claims

Weekly jobless claims rise in line with estimates Moderna and Pfizer in place as FDA clears updated COVID boosters Exxon climbs after strengthening its buyback program Indices up: Dow 0.55%, S&P 0.75%, Nasdaq 1.13% Dec 8 (Reuters) – The S&P 500 (.SPX) ended higher on Thursday, ending a five-game losing streak as investors interpreted data …

The S&P 500 and the Nasdaq chain losses following the rise in unemployment insurance claims Read More »

Elon Musk expects Neuralink brain chip to begin human trials in 6 months

Elon Musk expects Neuralink brain chip to begin human trials in 6 months

November 30 (Reuters) – Elon Musk said on Wednesday he expected a wireless brain chip developed by his company Neuralink to begin human clinical trials in six months, after the company missed the deadlines he had set. The company is developing brain chip interfaces that it says could help disabled patients move and communicate again, …

Elon Musk expects Neuralink brain chip to begin human trials in 6 months Read More »

Global stocks gain on hopes recession warning will force Fed's hand

Wall Street ends sharply lower, hit by concerns over Apple and China

Cyber ​​Monday spending will hit $11.6 billion – report Crypto stocks fall as BlockFi files for bankruptcy Biogen down after death in Alzheimer’s drug trial End of indices: S&P 500 -1.54%, Nasdaq -1.58%, Dow -1.45% Nov 28 (Reuters) – U.S. stocks ended sharply lower on Monday after protests in major Chinese cities over strict COVID-19 …

Wall Street ends sharply lower, hit by concerns over Apple and China Read More »

Roche's Alzheimer's drug fails in long-awaited trial

Roche’s Alzheimer’s drug fails in long-awaited trial

Trials show small benefit, but without statistical validity Roche setback leaves Biogen and Eisai as leaders in the field It’s up to Roche’s CEO-designate to revive development fortunes Roche shares down 3.4%, its development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) drug candidate for Alzheimer’s disease has not been shown to slow …

Roche’s Alzheimer’s drug fails in long-awaited trial Read More »